Coronary Artery Disease trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Coronary Artery Disease. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 2 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| HTFL | HeartFlow, Inc. | The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCINCT07479433observationalPrimary Endpoint | — | Recruiting | 2026-09-30 | in 41 d | 2026-03-23 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| GEHC | GE Healthcare | A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric PatientsNCT04604782Occurrence of Adverse Events (AEs) following administration of Regadenoson | Phase 1/2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-05-06 |
| HTFL | HeartFlow, Inc. | Using CTA Measures to Define Cardiac Risk In NFL AlumniNCT06831409observationalParticipants with CAD | — | Recruiting | 2026-12-31 | in 133 d | 2025-08-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Coronary Artery Disease
most recently updated first185 studies match. Showing the first 100 of 185 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDT | Medtronic | $117.9B | Product Surveillance RegistryNCT01524276observationalSafety and Effectiveness of Market Released products | — | Recruiting | — | Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder | 100,000 | Jan 2012 | Jan 2040 | ≤ 4,912 d | 2026-08-18 |
| LLY | Eli Lilly and Company | $1.15T | Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)NCT07157774Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint | Phase 3 | Recruiting | Drug: Muvalaplin, Placebo | Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD) | 10,450 | 2025-09-02 | Mar 2031 | ≤ 1,684 d | 2026-08-07 |
| SNY | Sanofi | — | Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic EventsNCT07734753observationalComposite of Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or All-Cause Mortality | — | Active, not recruiting | Drug: Alirocumab, Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents) | Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events | 4,006 | 2025-07-15 | 2026-05-15actual | — | 2026-07-29 |
| HUMA | Humacyte, Inc. | $162M | Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)NCT07730528Rate of events (MACE, AE, AESI, etc.) in all participants implanted with CTEV | Phase 2 | Not yet recruiting | Biological: Humacyte Coronary Tissue Engineered Vessel (CTEV) | Coronary Artery Disease | 10 | Sep 2026 | Sep 2030 | ≤ 1,502 d | 2026-07-28 |
| TFX | Teleflex | $5.6B | Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery LesionsNCT06779630Target Lesion Failure (TLF) rate at 12 months post-index procedure | Not applicable | Recruiting | Device: Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System | Coronary Artery Disease | 150 | 2025-07-18 | Sep 2027 | ≤ 406 d | 2026-07-24 |
| AMGN | Amgen | $229.9B | Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE]) | Phase 3 | Recruiting | Drug: Maridebart Cafraglutide, Placebo | Atherosclerotic Cardiovascular Disease, Overweight, Obesity | 12,800 | 2025-07-25 | 2028-06-30 | in 680 d | 2026-07-24 |
| TFX | Teleflex | $5.6B | Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery LesionsNCT07258290Target Lesion Failure (TLF) rate at 12 months post-index procedure | Not applicable | Recruiting | Device: Freesolve RMS, Xience DES | Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Chest Pain, Pain, Neurologic Manifestations, Signs and Symptoms, Pathological Conditions, Signs and Symptoms, Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Angina Pectoris | 1,859 | 2026-06-11 | Jun 2029 | ≤ 1,045 d | 2026-07-24 |
| BSX | Boston Scientific Corporation | $73.1B | Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)NCT04058990results2022-12-23Percentage of Participants With Events Included in the Primary Endpoint (Target Lesion Failure) | Not applicable | Completed | Device: Device: Paclitaxel-Coated PTCA Balloon Catheter, SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel | Coronary Artery Disease | 180 | 2019-12-12 | 2021-12-22actual | — | 2026-07-23 |
| OBIO | Orchestra BioMed, Inc | $340M | Virtue® SAB in the Treatment of Coronary ISR TrialNCT07045194Target Lesion Failure (TLF) at 12 months | Not applicable | Recruiting | Device: Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon | Coronary Artery Disease | 740 | 2025-10-20 | Oct 2028 | ≤ 803 d | 2026-07-23 |
| BSX | Boston Scientific Corporation | $73.1B | PROMUS PREMIER™ China Post-Approval StudyNCT03273023results2026-07-22observational12-month Major Adverse Cardiac Event (MACE) Rate | — | Completed | Device: Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System | Coronary Artery Disease | 2,059 | 2018-01-11 | 2020-12-28actual | — | 2026-07-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)NCT06292013Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint | Phase 3 | Active, not recruiting | Drug: Lepodisiran Sodium, Placebo | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 17,300 | 2024-03-05 | Mar 2029 | ≤ 954 d | 2026-07-20 |
| LLY | Eli Lilly and Company | $1.15T | The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390Time to First Occurrence of Composite Endpoints | Phase 3 | Active, not recruiting | Drug: Retatrutide, Placebo | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 10,000 | 2024-04-30 | Feb 2029 | ≤ 923 d | 2026-07-20 |
| SNY | Sanofi | — | Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical PracticeNCT07615166observationalMean Percentage Reduction in Low Density Lipoprotein Cholesterol (LDL-C) From Baseline Over the 60 to 450 Days Follow-up | — | Completed | Drug: Alirocumab 150 mg, Inclisiran | Atherosclerotic Cardiovascular Disease | 996 | 2025-05-22 | 2026-06-30actual | — | 2026-07-09 |
| AMGN | Amgen | $229.9B | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeNCT03872401results2026-06-25Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First | Phase 3 | Completed | Drug: Evolocumab, Placebo | Coronary Heart Disease (CHD) | 12,301 | 2019-06-11 | 2025-07-25actual | — | 2026-06-25 |
| SNY | Sanofi | — | Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)NCT07615179observationalComposite of nonfatal myocardial infarction, nonfatal ischemic stroke, or all-cause mortality | — | Completed | Drug: Alirocumab, Comparator: No PCSK9i Therapy (either mAb or siRNA) | Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events | 4,545 | 2025-02-17 | 2025-09-30actual | — | 2026-06-15 |
| HTFL | HeartFlow, Inc. | $3.9B | Assessing Diagnostic Value of Non-invasive FFR-CT in Coronary Care in the Emergency DepartmentNCT05325112observationalReclassification rate between the coronary management plan based on the review of the CCTA alone compared to the coronary management plan based on the review of the CCTA and the FFR-CT analysis. | — | Terminatedsponsor's stated reason: Sponsor decision to terminate the study | Diagnostic test: FFR-CT | Coronary Artery Disease | 18 | 2022-07-15 | 2022-11-14actual | — | 2026-05-22 |
| GEHC | GE Healthcare | $33.0B | A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric PatientsNCT04604782Occurrence of Adverse Events (AEs) following administration of Regadenoson | Phase 1/2 | Recruiting | Drug: Regadenoson | Myocardial Ischemia, Coronary Artery Disease | 54 | 2021-05-20 | Dec 2026 | ≤ 133 d | 2026-05-06 |
| LSTA | Lisata Therapeutics, Inc. | $10M | A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular DysfunctionNCT04614467results2026-05-04Change From Baseline in Number of Angina Attacks Per Week | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Biological: CLBS16, Placebo | Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease | 34 | 2020-10-29 | 2022-09-28actual | — | 2026-05-04 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe HypertriglyceridemiaNCT05355402results2026-04-23Percent Change From Baseline in Fasting TG at Month 6 | Phase 2 | Completed | Drug: Olezarsen, Placebo | Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia | 154 | 2022-05-09 | 2023-03-22actual | — | 2026-04-23 |
| HTFL | HeartFlow, Inc. | $3.9B | The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCINCT07479433observationalPrimary Endpoint | — | Recruiting | Diagnostic test: Heartflow PCI Navigator | Coronary Artery Disease (CAD) | 5,000 | 2026-03-11 | 2026-09-30 | in 41 d | 2026-03-23 |
| AMGN | Amgen | $229.9B | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes TrialNCT05581303Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first | Phase 3 | Active, not recruiting | Drug: Placebo, Olpasiran | Atherosclerotic Cardiovascular Disease | 7,297 | 2022-12-14 | 2028-03-31 | in 589 d | 2026-02-27 |
| AZN | AstraZeneca | — | A Study to Assess the Effect of AZD0780 on Ambulatory Blood PressureNCT06692764To assess the effect of treatment with AZD0780 dose 1 versus placebo on ambulatory 24-hour average SBP at Week 4 | Phase 2 | Completed | Drug: Placebo, AZD0780 | Atherosclerotic Cardiovascular Disease | 202 | 2024-10-30 | 2025-04-18actual | — | 2026-02-18 |
| NVO | Novo Nordisk A/S | — | Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure ManagementNCT07160829observationalPerceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease, Heart Failure, Chronic Kidney Disease | 608 | 2025-09-18 | 2025-10-30actual | — | 2026-02-11 |
| NVO | Novo Nordisk A/S | — | A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real WorldNCT07141914observationalRevised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) | — | Completed | Other: No treatment given, No treatment given | Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention | 285,327 | 2025-08-29 | 2025-12-19actual | — | 2026-01-23 |
| NVO | Novo Nordisk A/S | — | A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and NephrologistsNCT06589791observationalHealth care professional's perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 1,500 | 2024-09-09 | 2024-12-05actual | — | 2025-12-05 |
| AZN | AstraZeneca | — | A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.NCT06675175Number of participants with adverse events | Phase 1 | Completed | Drug: AZD4144 · Other: Placebo | Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease | 29 | 2024-12-09 | 2025-10-27actual | — | 2025-11-25 |
| AMGN | Amgen | $229.9B | A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)NCT05378529Number of participants with elevated Lp(a) with documented history of ASCVD | Not applicable | Completed | Other: Lp(a) Screening | Atherosclerotic Cardiovascular Disease | 39,480 | 2022-04-19 | 2023-12-30actual | — | 2025-10-27 |
| HTFL | HeartFlow, Inc. | $3.9B | AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD ManagementNCT06376851observationalPrimary Endpoint | — | Active, not recruiting | Diagnostic test: AI-enabled quantitative coronary plaque analysis (AI-QCPA) | Coronary Artery Disease | 20,000 | 2024-03-27 | 2026-03-27 | — | 2025-10-14 |
| OGN | Organon and Co | $3.6B | Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk PatientsNCT05761444results2025-09-09Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 6 | Phase 4 | Completed | Drug: Atozet 10/40 mg or 10/80 mg, Lipitor 40 mg or 80 mg | Atherosclerotic Cardiovascular Disease | 137 | 2023-07-26 | 2024-09-04actual | — | 2025-09-09 |
| HTFL | HeartFlow, Inc. | $3.9B | The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)NCT01943903results2025-09-05observationalNumber of Participants With Negative Invasive Coronary Angiography | — | Completed | — | Coronary Artery Disease | 584 | Sep 2013 | Dec 2015actual | — | 2025-09-05 |
| HTFL | HeartFlow, Inc. | $3.9B | Using CTA Measures to Define Cardiac Risk In NFL AlumniNCT06831409observationalParticipants with CAD | — | Recruiting | Diagnostic test: Coronary computed tomography angiography | Coronary Artery Disease (CAD), Heart Disease, Coronary Atherosclerosis | 300 | 2024-12-17 | 2026-12-31 | in 133 d | 2025-08-26 |
| HTFL | HeartFlow, Inc. | $3.9B | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CareNCT02499679results2025-07-30observationalPercentage of Participants With Reclassification of CAD Management, Assessed as the Therapeutic Recommendations Made Based on Review of Coronary CTA Alone Versus CTA + FFRCT, When Available, by a Central Integration Core Laboratory. | — | Completed | — | Coronary Artery Disease | 4,737 | Jul 2015 | Feb 2019actual | — | 2025-07-30 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart DiseaseNCT04992065results2025-06-08Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol | Phase 2 | Completed | Drug: NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, NNC0385-0434 A 100 mg, Evolocumab 140 mg/mL, Repatha® · Other: Placebo I A (for NNC0385-0434 A 15 mg), Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg) | Atherosclerotic Cardiovascular Disease | 267 | 2021-08-03 | 2022-04-26actual | — | 2025-06-08 |
| NVO | Novo Nordisk A/S | — | Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real WorldNCT06874751observationalRevised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) | — | Completed | Other: No treatment given, No treatment given | Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD) | 45,456 | 2024-12-06 | 2025-03-28actual | — | 2025-05-21 |
| EW | Edwards Lifesciences | $52.4B | Magna® Mitral Pericardial Bioprostheses Post-Approval Study ProtocolNCT00853632results2025-05-14Subject's Rate of Objective Performance Criteria Per ISO 5840-2005 - Total Number of Late Adverse Events (by Category) Divided by Late Patient Years (Expressed as a Percentage) for the Magna Mitral Valve Implanted Cohort | Not applicable | Completed | Device: CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES | Coronary Artery Disease, Mitral Valve Regurgitation, Mitral Valve Incompetence, Heart Failure | 329 | Aug 2007 | 2024-03-06actual | — | 2025-05-14 |
| SNY | Sanofi | — | Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injectorNCT05129241observationalAbsolute change from baseline to week 12 in low-density lipoprotein cholesterol (LDL-C) | — | Completed | — | Primary Hypercholesterolaemia and Mixed Dyslipidaemia, Atherosclerotic Cardiovascular Disease | 163 | 2021-11-18 | 2023-02-16actual | — | 2025-03-24 |
| BSX | Boston Scientific Corporation | $73.1B | Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ StentNCT01285999results2024-11-209 Month In-stent Late Loss | Not applicable | Completed | Device: PROMUS Element Coronary Stent System, TAXUS Liberté Coronary Stent System | Atherosclerosis, Coronary Artery Disease | 500 | Jan 2011 | Mar 2013actual | — | 2025-03-11 |
| AZN | AstraZeneca | — | Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial InfarctionNCT04610892results2025-02-21Change From Baseline to Day 253 in Non-calcified Plaque Volume in the Most Diseased Coronary Segment (NCPVMD), as Measured by Computed Tomography Angiography (CTA) Imaging | Phase 2 | Completed | Biological: MEDI6570, Placebo | Coronary Heart Disease (CHD) | 423 | 2020-11-04 | 2023-11-08actual | — | 2025-02-21 |
| 000100.KS | Yuhan Corporation | $4.2B | A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery DiseaseNCT05730621Change from baseline to week 12 in Blood Viscosity(cP, centipoise) measured by the blood viscometer | Phase 4 | Completed | Drug: Sarpogrelate Sustained Release/Aspirin, Aspirin | Sarpogrelate, Blood Viscosity, Peripheral Arterial Disease, Coronary Artery Disease | 68 | 2023-01-11 | 2024-02-28actual | — | 2025-01-22 |
| GEHC | GE Healthcare | $33.0B | Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary PlaqueNCT06186336observationalData Collection | — | Not yet recruiting | Other: Deep Learning-based Vulnerable Plaque Detection and Assessment Tool | Chronic Coronary Syndrome, Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome | 200 | Jan 2025 | Jun 2025 | — | 2025-01-07 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)NCT01334918results2013-09-18Number of Participants With Reversible Defects | Phase 2 | Completed | Drug: regadenoson · Radiation: technetium Tc99m sestamibi /technetium Tc99m tetrafosmin, Contrast · Procedure: Single Photon Emission Computed Tomography, Multidetector Computed Tomography | Coronary Artery Disease (CAD) | 124 | 2011-04-26 | 2012-07-02actual | — | 2024-12-04 |
| 4503.T | Astellas Pharma Inc | $26.0B | Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)NCT00826280results2011-10-21Change in Number of Reversible Defects | Phase 3 | Completed | Drug: regadenoson, overencapsulated caffeine, placebo · Radiation: technetium | Coronary Artery Disease (CAD) | 347 | 2009-03-24 | 2010-07-15actual | — | 2024-12-03 |
| OGN | Organon and Co | $3.6B | Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)NCT00651274Percent change from baseline in LDL-cholesterol with ezetimibe added to simvastatin versus continued simvastatin alone. | Phase 4 | Completed | Drug: Ezetimibe, Placebo | Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease | 144 | 2003-04-01 | 2004-08-01actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)NCT00651378Percent change in LDL-C level from baseline to the study endpoint. | Phase 4 | Terminatedsponsor's stated reason: Slow enrollment \[HIGH SCREEN FAILURE RATE\] | Drug: Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin | Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease | 87 | 2004-09-01 | 2005-06-01actual | — | 2024-08-15 |
| NVO | Novo Nordisk A/S | — | A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among NephrologistsNCT06322641observationalNephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation | 300 | 2024-03-26 | 2024-05-10actual | — | 2024-07-26 |
| NVS | Novartis | — | A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial HypercholesterolemiaNCT06507852observationalPercentage of Patients who Received Inclisiran Dose 2 and 3 Within Specified Time Intervals | — | Completed | — | Atherosclerotic Cardiovascular Disease, Hypercholesterolemia | 95 | 2022-10-03 | 2023-07-06actual | — | 2024-07-18 |
| BSX | Boston Scientific Corporation | $73.1B | Vortex - Temporary Percutaneous, Transvalvular Circulatory Support System Feasibility StudyNCT04674111results2024-04-24Number of Participants With Technical Success | Not applicable | Completed | Device: Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System) | Coronary Artery Disease | 5 | 2021-09-28 | 2022-04-08actual | — | 2024-04-24 |
| NVO | Novo Nordisk A/S | — | A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese MenNCT05003440Number of treatment emergent adverse events (TEAEs) | Phase 1 | Completed | Drug: NNC0385-0434, Placebo | Healthy Volunteers, Atherosclerotic Cardiovascular Disease | 36 | 2021-08-19 | 2022-01-19actual | — | 2024-01-17 |
| HTFL | HeartFlow, Inc. | $3.9B | The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and RevascularizationNCT03702244results2023-12-29Primary Composite (Number) of Deaths / MIs / Invasive Coronary Angiography Without Obstructive Disease | Not applicable | Completed | Diagnostic test: cCTA with selective FFRct | Coronary Artery Disease | 2,103 | 2018-11-27 | 2022-05-20actual | — | 2023-12-29 |
| BSX | Boston Scientific Corporation | $73.1B | A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)NCT03875651observationalTarget Lesion Failure (TLF) rate | — | Completed | Device: SYNERGY 4.50 mm and 5.0 mm Coronary Stent System | Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases | 100 | 2019-05-09 | 2022-01-07actual | — | 2023-12-14 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy ParticipantsNCT05093790results2023-12-05Percent Change From Baseline in Thrombus Area | Phase 2 | Completed | Drug: Ticagrelor, BMS-986141, Aspirin | Coronary Artery Disease, Healthy Participants | 58 | 2022-03-25 | 2022-11-14actual | — | 2023-12-05 |
| BSX | Boston Scientific Corporation | $73.1B | The EVOLVE China Clinical TrialNCT01966159results2016-02-18The In-stent Late Loss Measured by Quantitative Coronary Angiography | Not applicable | Completed | Device: SYNERGY Investigational Device, PE Plus Investigational Device | Coronary Artery Disease | 412 | Oct 2013 | Jul 2014actual | — | 2023-11-15 |
| BSX | Boston Scientific Corporation | $73.1B | A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent SystemNCT04807439observationalTarget Lesion Failure (TLF) rate | — | Completed | Device: SYNERGY XLV (Megatron) Coronary Stent System | Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases | 100 | 2021-04-14 | 2022-08-19actual | — | 2023-10-23 |
| GEHC | GE Healthcare | $33.0B | A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing ProcessesNCT04594941results2023-08-01Intra-reader Difference of Summed Rest Score (SRS) for Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) | Phase 2 | Completed | Drug: Flurpiridaz (18F) Injection | Coronary Artery Disease (CAD), Ischemic Heart Disease | 38 | 2022-01-27 | 2022-05-26actual | — | 2023-08-01 |
| ELUT | Elutia Inc. | $42M | Retrospective Experience Of CIED ImplantationNCT04351269results2022-05-18observationalNumber of Participants With Major Infection Post Procedure | — | Completed | Device: CanGaroo Envelope, TYRX Envelope | Cardiac Disease, Heart Failure, Coronary Artery Disease | 597 | 2020-04-22 | 2021-06-30actual | — | 2023-07-21 |
| GEHC | GE Healthcare | $33.0B | An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)NCT03354273results2023-07-12Sensitivity and Specificity of Flurpiridaz (18F) Injection Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in the Detection of Significant Coronary Artery Disease (CAD) as Defined by Cardiac Catheterization | Phase 3 | Completed | Drug: PET MPI, SPECT MPI, Pharmacological stress agents | Coronary Artery Disease (CAD) | 730 | 2018-06-05 | 2022-05-05actual | — | 2023-07-12 |
| NVO | Novo Nordisk A/S | — | A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among CardiologistsNCT05755373observationalCardiologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD. Multi-select from a defined list. | — | Completed | Other: No treatment given | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 602 | 2023-03-24 | 2023-05-15actual | — | 2023-06-09 |
| BSX | Boston Scientific Corporation | $73.1B | FAST Feasibility StudyNCT02470884Clinical Procedural Success | Not applicable | Completed | Device: Boston Scientific Fully Absorbable Scaffold | Coronary Artery Disease | 33 | 2015-06-15 | 2017-01-31actual | — | 2022-06-22 |
| AMGN | Amgen | $229.9B | Imaging of Coronary Plaques in Participants Treated With EvolocumabNCT03570697results2021-11-24Absolute Change From Baseline in Minimum FCT | Phase 3 | Completed | Drug: Evolocumab, Placebo, Statin therapy | Coronary Artery Disease (CAD) | 164 | 2018-11-19 | 2020-12-18actual | — | 2022-05-03 |
| SNY | Sanofi | — | An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular EventNCT03099213Total patients with tolerability score Very Good | Phase 4 | Completed | Drug: RAMIPRIL HOE498 | Coronary Artery Disease | 179 | 2008-11-01 | 2010-04-23actual | — | 2022-04-25 |
| SNY | Sanofi | — | Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes MellitusNCT03462017Change in Flow Mediated Dilation (FMD) | Phase 1 | Completed | Drug: SAR247799, Placebo, Sildenafil, Acetylcholine | Microvascular Coronary Artery Disease | 54 | 2018-03-07 | 2018-12-22actual | — | 2022-04-25 |
| SNY | Sanofi | — | A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCINCT03236311results2019-07-11Change From Baseline in Uncorrected Global Coronary Flow Reserve (CFR) at Week 4 | Phase 2 | Terminatedsponsor's stated reason: (Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.) | Drug: SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium | Microvascular Coronary Artery Disease | 10 | 2017-10-12 | 2018-07-23actual | — | 2022-03-24 |
| BSX | Boston Scientific Corporation | $73.1B | Post-Approval Study of PROMUS Element™ in ChinaNCT01677585observationalTarget Lesion Failure (TLF) rate | — | Completed | — | Coronary Artery Disease | 2,016 | Aug 2012 | Dec 2015actual | — | 2022-02-24 |
| OGN | Organon and Co | $3.6B | Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)NCT00650689Change from baseline to endpoint in LDL-C. | Phase 3 | Completed | Drug: Ezetimibe + Atorvastatin, Atorvastatin | Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease | 122 | May 2003 | Dec 2004actual | — | 2022-02-17 |
| OGN | Organon and Co | $3.6B | Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)NCT00202904To compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg versus placebo added daily to ongoing treatment with atorvastatin 10 mg in reducing the concentration of LDL-C at endpoint | Phase 4 | Completed | Drug: ezetimibe, placebo | Hypercholesterolemia, Coronary Heart Disease | 81 | May 2005 | Oct 2006actual | — | 2022-02-16 |
| OGN | Organon and Co | $3.6B | Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)NCT00723723observationalpercentage of patients reaching target LDL levels | — | Completed | Drug: Statin | Coronary Heart Disease, Hypercholesterolemia, Hyperlipidemia | 555 | Jan 2008 | Jun 2009actual | — | 2022-02-16 |
| OGN | Organon and Co | $3.6B | Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)NCT00730132results2010-10-11observationalPercentage of Patients Receiving Each Variant of Modified Lipid-lowering Therapy: Statin Dose Titration, Administration of a New Statin, Administration of a Ezetimibe in Addition to a Current Statin. | — | Completed | Drug: Ezetimibe, Statin | Coronary Heart Disease, Hypercholesterolemia | 712 | Jan 2008 | Aug 2009actual | — | 2022-02-09 |
| GEHC | GE Healthcare | $33.0B | Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast MediumNCT03671603observationalAssessment of the Incidence Rate of AKI in STEMI Participants Undergoing Primary PCI Using Visipaque | — | Completed | Drug: Iodixanol | Coronary Artery Disease, ST-segment Elevation Myocardial Infarction | 2,755 | 2018-11-05 | 2021-06-07actual | — | 2022-01-11 |
| ZBH | Zimmer Biomet | $18.9B | Clinical Outcomes in Patients Treated With SternaLock BluNCT03709693observationalDeep Sternal Wound Infection Rate | — | Terminatedsponsor's stated reason: COVID 19 Pandemic | Device: SternaLock Blu | Cardiac Surgical Procedures, Coronary Artery Disease, Heart Valve Diseases | 156 | 2019-05-14 | 2020-05-13actual | — | 2021-07-23 |
| BSX | Boston Scientific Corporation | $73.1B | Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)NCT04059536observationalNumber of Participants with a Successful Index Procedure by Roxwood Medical Device(s) | — | Withdrawnsponsor's stated reason: Sponsor decision | Device: Roxwood Anchoring Catheters · Drug: Acetylsalicylic Acid, Heparin | Chronic Total Occlusion, Atherosclerosis, Coronary Artery Disease, Peripheral Artery Disease | 0 | 2019-10-31 | 2019-12-01 | — | 2021-07-21 |
| AZN | AstraZeneca | — | AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).NCT03317002results2021-06-30Change From Baseline in Creatinine-normalized u-LTE4 at Week 4 | Phase 2 | Completed | Drug: AZD5718, AZD5718, Placebo | Coronary Artery Disease | 129 | 2017-10-30 | 2020-04-08actual | — | 2021-06-30 |
| 4568.T | Daiichi Sankyo | $31.7B | Prasugrel/Clopidogrel Maintenance Dose Washout StudyNCT01014624results2011-09-09The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline | Phase 4 | Completed | Drug: Prasugrel, Clopidogrel | Coronary Artery Disease | 56 | Feb 2010 | May 2010actual | — | 2021-06-28 |
| BSX | Boston Scientific Corporation | $73.1B | A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)NCT03350542results2021-02-05Target Lesion Failure Rate at 12-months | Phase 3 | Completed | Device: SYNERGY 48 mm | Coronary Artery Disease | 100 | 2018-04-12 | 2020-01-16actual | — | 2021-05-14 |
| ESPR | Esperion Therapeutics, Inc. | — | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)NCT03067441results2020-12-22Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Completed | Drug: bempedoic acid | Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | 1,462 | 2017-02-03 | 2019-11-05actual | — | 2021-03-01 |
| HTFL | HeartFlow, Inc. | $3.9B | Determination of Fractional Flow Reserve by Anatomic Computed Tomographic AngiographyNCT01233518results2021-01-22Percentage of Participants With Diagnostic Accuracy of CCTA Plus FFRCT and CCTA Alone | Not applicable | Completed | Device: FFR | Coronary Artery Disease | 285 | Oct 2010 | Nov 2011actual | — | 2021-02-09 |
| BSX | Boston Scientific Corporation | $73.1B | CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) StudyNCT00801710CTO Crossing Rate | Not applicable | Completed | Device: BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire) | Coronary Artery Disease, Coronary Artery Chronic Total Occlusion | 42 | Sep 2008 | Jun 2009actual | — | 2021-01-26 |
| NVS | Novartis | — | Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)NCT00568594Safety and tolerability, pharmacokinetics and effects on biomarkers of HDL function of APL180 after a single and 7-daily infusions in healthy volunteers (HV) and in patients with coronary heart disease (CHD) | Phase 1/2 | Completed | Drug: APL180, Placebo | Coronary Heart Disease | 176 | Nov 2007 | Sep 2009actual | — | 2020-12-24 |
| 000100.KS | Yuhan Corporation | $4.2B | High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 DiabetesNCT03403556Mean percent change from baseline to week 24 in low-density lipoprotein cholesterol (LDL-C) | Phase 4 | Unknown status | Drug: Rosuvamibe, Monorova | Atherosclerotic Cardiovascular Disease, Type 2 Diabetes | 140 | 2018-03-27 | Oct 2021 | — | 2020-12-14 |
| 000100.KS | Yuhan Corporation | $4.2B | Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DMNCT03597412Change from baseline to week 24 in LDL-C level | Phase 4 | Completed | Drug: Rosuvamibe, Monorova | Atherosclerotic Cardiovascular Disease, Type 2 Diabetes Mellitus | 236 | 2018-10-17 | 2020-08-12actual | — | 2020-12-14 |
| BSX | Boston Scientific Corporation | $73.1B | EVOLVE Short DAPT StudyNCT02605447results2020-09-25Number of Participants Who Experienced Death or Myocardial Infarction (MI) | Phase 4 | Completed | Drug: 3 months of dual antiplatelet therapy (DAPT) · Device: SYNERGY Stent System | Coronary Artery Disease | 2,009 | 2016-02-16 | 2019-07-17actual | — | 2020-09-25 |
| ESPR | Esperion Therapeutics, Inc. | — | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular RiskNCT02991118results2020-04-27Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) | Phase 3 | Completed | Drug: bempedoic acid, placebo | Hypercholesterolemia, Atherosclerotic Cardiovascular Disease | 779 | 2016-11-18 | 2018-08-22actual | — | 2020-04-27 |
| EW | Edwards Lifesciences | $52.4B | Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFXNCT01171625results2020-04-17Subject's Percentage of Long Term Safety Performance | Not applicable | Completed | Device: Implantation of CEP Magna Ease Model 3300TFX | Coronary Artery Disease, Aortic Valve Disorder, Heart Failure, Aortic Valve Stenosis, Aortic Valve Insufficiency | 283 | Oct 2007 | Sep 2018actual | — | 2020-04-17 |
| ESPR | Esperion Therapeutics, Inc. | — | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin IntolerantNCT02988115results2020-04-03Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 | Phase 3 | Completed | Drug: bempedoic acid · Other: placebo | Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction | 345 | 2016-11-16 | 2018-03-16actual | — | 2020-04-03 |
| AZN | AstraZeneca | — | A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy VolunteersNCT04210388Area under the plasma concentration-time curve from zero to infinity (AUC) | Phase 1 | Completed | Drug: AZD5718 tablet, Formulation A, AZD5718 tablet, Formulation B, AZD5718 tablet, Formulation C, AZD5718 tablet, Formulation D, AZD5718 film-coated tablet, Reference treatment | Coronary Artery Disease (CAD) | 12 | 2020-01-14 | 2020-03-09actual | — | 2020-03-25 |
| AZN | AstraZeneca | — | A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718NCT04087187Pharmacokinetic parameter: Area under plasma concentration time curve from zero to infinity (AUC) | Phase 1 | Completed | Drug: Treatment A, Treatment B, Treatment C | Coronary Artery Disease | 14 | 2019-09-20 | 2019-10-31actual | — | 2019-11-15 |
| EW | Edwards Lifesciences | $52.4B | Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000NCT01651052results2019-07-26Number of Early Adverse Events Divided by Number of Subjects (Expressed as a Percentage) | Not applicable | Completed | Procedure: Heart Valve Surgery | Aortic Valve Disorder, Aortic Valve Insufficiency, Aortic Valve Stenosis, Heart Failure, Coronary Artery Disease | 133 | Jul 2011 | Jul 2018actual | — | 2019-07-26 |
| BSX | Boston Scientific Corporation | $73.1B | PLATINUM DiversityNCT02240810results2019-05-10observationalComposite Rate of Death, Myocardial Infarction (MI), and Target Vessel Revascularization (TVR) | — | Completed | Device: Percutaneous coronary intervention (Promus PREMIER) | Atherosclerosis, Coronary Artery Disease | 1,501 | Oct 2014 | Sep 2016actual | — | 2019-05-15 |
| GEHC | GE Healthcare | $33.0B | A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCTNCT00350506 | Not applicable | Terminatedsponsor's stated reason: Sponsor decision (due to low subject enrollment) | Device: 64 Channel VCT | Coronary Artery Disease | 77 | Oct 2005 | Oct 2006actual | — | 2019-04-30 |
| GEHC | GE Healthcare | $33.0B | Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary AngiographyNCT00335101Primary endpoint: | Phase 4 | Withdrawnsponsor's stated reason: Sponsor Decision to withdraw study (comparative product withdrawn from the market) | Drug: Iodixanol, Ioversol, Iopromide | Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus | 0 | Jun 2006 | — | — | 2019-04-29 |
| GEHC | GE Healthcare | $33.0B | A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest PainNCT00348569 | Not applicable | Completed | Device: 64 Channel VCT | Coronary Artery Disease | 245 | May 2006 | 2007-01-31actual | — | 2019-04-29 |
| GEHC | GE Healthcare | $33.0B | Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the HeartNCT00335335To evaluate diagnostic performance and safety of Visipaque-enhanced CTA images for determination of presence or absence of coronary artery obstruction | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision due to low subject recrcuitment | Drug: iodixanol | Coronary Artery Disease | 89 | May 2006 | 2006-12-02actual | — | 2019-04-25 |
| GEHC | GE Healthcare | $33.0B | Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the HeartNCT00348608To evaluate diagnostic performance and safety of Visipaque-enhanced CTA images for determination of presence or absence of coronary artery obstruction | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision (due to low subject recruitment) | Drug: iodixanol | Coronary Artery Disease | 66 | Jun 2006 | 2006-12-02actual | — | 2019-04-25 |
| BSX | Boston Scientific Corporation | $73.1B | The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery LesionsNCT00823212results2012-01-27Target Lesion Failure (TLF) | Phase 3 | Completed | Device: PROMUS Coronary Stent System, PROMUS Element Coronary Stent System · Drug: Aspirin, Thienopyridine | Coronary Artery Disease | 1,530 | Jan 2009 | Sep 2010actual | — | 2019-03-27 |
| BSX | Boston Scientific Corporation | $73.1B | The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small VesselsNCT01498692results2012-02-13Target Lesion Failure (TLF) | Not applicable | Completed | Device: PROMUS Element Coronary Stent System | Coronary Artery Disease | 94 | Feb 2009 | Dec 2010actual | — | 2019-03-26 |
| BSX | Boston Scientific Corporation | $73.1B | The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)NCT01500434results2012-02-14Target Lesion Failure (TLF) | Phase 3 | Completed | Device: PROMUS Element Coronary Stent System · Drug: Aspirin, Thienopyridine | Coronary Artery Disease | 102 | Feb 2009 | Mar 2011actual | — | 2019-03-26 |
| BSX | Boston Scientific Corporation | $73.1B | PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)NCT01510327results2012-04-05Maximum Observed Everolimus Blood Concentration (Cmax) | Phase 3 | Completed | Device: PROMUS Element Everolimus-Eluting Coronary Stent System · Drug: Aspirin, Thienopyridine | Coronary Artery Disease | 22 | Oct 2009 | Feb 2010actual | — | 2019-03-26 |
| SNY | Sanofi | — | ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabNCT01663402results2019-03-18Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study | Phase 3 | Completed | Drug: Alirocumab, Placebo, LMT | Atherosclerotic Cardiovascular Disease | 18,924 | Oct 2012 | 2018-01-23actual | — | 2019-03-18 |
| BSX | Boston Scientific Corporation | $73.1B | The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)NCT01665053results2016-01-07Percentage of Participants With Target Lesion Failure (TLF) at 12 Months | Phase 3 | Completed | Device: PROMUS Element Plus, SYNERGY | Coronary Artery Disease | 1,684 | Nov 2012 | Sep 2014actual | — | 2019-01-30 |
| 4568.T | Daiichi Sankyo | $31.7B | The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery DiseaseNCT01260584results2012-12-12Inhibition of Platelet Aggregation (IPA) in Prasugrel-treated and Clopidogrel-treated Smokers and Non-smokers Following 9 Days of Maintenance Therapy. | Phase 4 | Completed | Drug: Prasugrel, Clopidogrel | Coronary Artery Disease | 110 | Nov 2010 | Sep 2011actual | — | 2019-01-09 |
| 4568.T | Daiichi Sankyo | $31.7B | Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery DiseaseNCT01587651results2014-04-29P2Y12 Reaction Units | Phase 4 | Completed | Drug: Prasugrel Loading Dose, Prasugrel Maintenance Dose, Ticagrelor Maintenance Dose | Coronary Artery Disease | 110 | Mar 2012 | Feb 2013actual | — | 2019-01-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Coronary Artery Disease is matched — 9 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Coronary Artery Disease
- Coronary Heart Disease
- Atherosclerotic Cardiovascular Disease
- Coronary Artery Disease (CAD)
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Stable Coronary Artery Disease
- Microvascular Coronary Artery Disease
- Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
- Coronary Heart Disease (CHD)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Coronary Artery Disease” (a text search, wider than this page)